About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
SABCS 2020 RxPONDER Updates on HR+ Node-Positive EBC: Are Postmenopausal Women Able to Avoid Chemotherapy?
By
Steven Vogl
18 Videos
2,044 views
December 29, 2020
1 Comment
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
12:35
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…
Feat.
S. Tolaney,
H. Rugo
14:16
Dana-Farber Cancer Institute
Year in Review: Breast Cancer
Feat.
P. Tarantino
10:27
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Role for CDK 4/6i in the Adjuv…
Feat.
S. Tolaney,
H. Rugo
24:10
Keck School of Medicine of USC
CDK4/6 Inhibitors in Breast Cancer: 2024 Update
Feat.
R. O'Regan
21:37
Dana-Farber Cancer Institute
Standard Treatments for HR+/HER2- mBC in 2023
Feat.
S. Sammons
23:13
Keck School of Medicine of USC
NRG-BR009 ("OFSET") Study: Evaluating the Addition of Adju…
Feat.
T. Mamounas
27:01
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024
CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC
Feat.
S. Sammons
03:24
ecancer
SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…
Feat.
V. Kaklamani
29:44
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023
Optimal Duration of Endocrine Therapy for Breast Cancer
Feat.
V. Kaklamani
20:16
University of Colorado Cancer Center
Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…
Feat.
V. Borges
18:11
Nagi El Saghir
ABC7 2023 International Consensus Guidelines: Select Guidelines for …
12:24
Stanford Medicine
HR+ mBC: CDK4/6i Progression Management
Feat.
M. Dolezal
13:32
13th Annual Winter Breast Cancer Symposium
2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs
Feat.
W. Gradishar
08:48
James Martin
2L Therapy for ER+ mBC Following CDK4/6i
22:49
Oncology Data Advisor
Highlights of the 2023 SABCS: HER2CLIMB-02, MONARCH3, and INAVO120 T…
Feat.
J. Mouabbi
08:54
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for Pat…
Feat.
S. Tolaney,
H. Rugo
14:54
Grace Choong
Resistance Mutations in HR+ mBC After 1L ET + CDK4/6i: Next Lines an…
22:29
ESMO 2022 Conference Coverage
ESMO 2022 on Adjuvant Endocrine Therapy for BC: Who Needs More Than …
Feat.
E. de Azambuja
03:04
Insights from 2023 SABCS
SABCS 2023 Insights: "The Future of Oral SERDs in Breast Cancer…
Feat.
E. Hamilton
17:12
Total Health
Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…
Feat.
R. O'Regan
